title: Intragraft interleukin-4 mRNA expression after short-term CD154 blockade may trigger delayed development of transplant arteriosclerosis in the absence of CD8+ T cells.
abstract: BACKGROUND
  It has recently been shown that, although anti-CD154 induces CD4+ T-cell tolerance, it is unable to prevent allograft rejection mediated by CD8+ T cells. We have also shown that anti-CD154 monotherapy does not protect the graft from the development of transplant arteriosclerosis even in the absence of CD8+ T cells. This study was designed to investigate and characterize possible mechanisms responsible for the development of transplant arteriosclerosis after CD154 blockade in the absence of CD8+ T cells.
  
  
  METHODS
  C57BL/6 (H2b) recipients received a fully MHC-mismatched BALB/c donor aorta (H2d). Animals were either treated with anti-CD154 monoclonal antibody (mAb) in the presence or absence of CD8 T cells. Histology, morphometric measurements, immunohistochemistry, and the production of alloantibodies (IgM, IgG1, IgG2a) were analyzed on days 14, 30, and 50 after transplantation. Cytokine production within the graft was investigated by competitive reverse transcription-polymerase chain reaction on day 14.
  
  
  RESULTS
  Combined treatment with anti-CD154 and a depleting CD8 mAb resulted in a delay in the development of transplant arteriosclerosis (intimal proliferation: 33+/-10% vs. 67+/-11% untreated control, day 30) but ultimately did not prevent its progression (intimal proliferation: 55+/-10% vs. 78+/-9% untreated control, day 50). Although there was a significant decrease in the number of CD4+, CD11b+, and CD40+ graft-infiltrating cells and a reduction in the formation of donor-specific IgG1 alloantibodies in recipients treated with anti-CD154 and anti-CD8 mAbs, mRNA for interleukin (IL)-4 was increased, suggesting a shift in the intragraft cytokine profile towards a Th2-like pattern.
  
  
  CONCLUSIONS
  Our data provide evidence that short-term CD154 blockade is insufficient to prevent transplant arteriosclerosis, even in combination with CD8+ T-cell depletion. Moreover, the increased expression of the Th2 cytokine interleukin-4 within the graft may be responsible for the development of transplant arteriosclerosis in the long term.
authors.affiliation: Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, United Kingdom.
authors.forename: S M
authors.initials: SM
authors.lastname: Ensminger
authors.forename: B M
authors.initials: BM
authors.lastname: Spriewald
authors.forename: O
authors.initials: O
authors.lastname: Witzke
authors.forename: K
authors.initials: K
authors.lastname: Morrison
authors.forename: A
authors.initials: A
authors.lastname: van Maurik
authors.forename: P J
authors.initials: PJ
authors.lastname: Morris
authors.forename: M L
authors.initials: ML
authors.lastname: Rose
authors.forename: K J
authors.initials: KJ
authors.lastname: Wood
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D001011:Aorta / Q000737:chemistry / Q000637:transplantation*; D001161:Arteriosclerosis / Q000209:etiology*; D023201:CD40 Ligand / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology*; D007150:Immunohistochemistry; D015847:Interleukin-4 / Q000235:genetics*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010641:Phenotype; D012333:RNA, Messenger / Q000096:biosynthesis*; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects* / Q000473:pathology
chemical_list: D019138:Antibodies, Blocking; D012333:RNA, Messenger; D023201:CD40 Ligand; D015847:Interleukin-4